Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Sezzle expects to exceed its previously announced 55% revenue growth target for FY2024.,Strong Profitability,: The company ...

Azul and Abra sign a Memorandum of Understanding (MoU) to combine Azul and Gol's operations, aiming to elevate Brazil's ...

BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene Stock A Buy? BeiGene stock reclaimed its 50 ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

EDWARDSVILLE - Metro-East Lutheran High School Metro-East Lutheran High School Second Quarter Honor Roll 2024-2025 The ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

The news media is too focused on small moves in Nvidia stock when they should be considering longer-term trends, a Wall ...